For the Inventor, By the Inventor

Enter assignee name

Rahway, NJ, United States of America

Merck Sharp & Dohme LLC

USPTO Granted Patents = 67

CIPO Patents = 35

EPO Patents = 65

Forward Citations = 0

Loading Chart...

Loading Chart...

506 inventors (with patents filed for the assignee):

Jian Liu (6 out of 40 patents)

Xavier Fradera (5 out of 24 patents)

Shuhei Kawamura (5 out of 8 patents)

4. Kira A Armacost (5 out of 5 patents)

5. Dong Xiao (4 out of 45 patents)

6. Michael T Rudd (4 out of 35 patents)

7. David L Sloman (4 out of 38 patents)

8. Peter J Manley (4 out of 29 patents)

9. Peter H Fuller (4 out of 22 patents)

10. Izzat Tiedje Raheem (4 out of 28 patents)

11. Brandon A Vara (4 out of 6 patents)

12. Danielle M Hurzy (4 out of 4 patents)

13. Dane James Clausen (4 out of 4 patents)

14. Michelle Machacek (4 out of 4 patents)

15. Ian M Bell (3 out of 73 patents)

Core Competencies:

BTK Inhibitor

Cytotoxic Agents

KRAS Inhibitors

Orexin Receptor Agonists

RSV Antibodies

PRMT5 Inhibitors

Nucleotides Synthesis

Antimalarial Agents

Vaccine Development

Histone Deacetylase Inhibitors

Lipid Nanoparticles

Fluorinated Nucleotides

67 patents: Sort by Forward Citations

1. 12753190 - Spirotricycle RIPK1 inhibitors and methods of uses thereof (2026-10-06),

2. 12753187 - Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses (2026-10-06),

3. 12753163 - Diaminopyrimidine carboxamide inhibitors of HPK1 (2026-10-06),

4. 12747244 - SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF (2026-09-29),

5. 12735506 - ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY (2026-09-15),

6. 12735431 - 7-phenyl substituted 2-aminoquinazoline inhibitors of HPK1 (2026-09-15),

7. 12735425 - 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT (2026-09-15),

8. 12735409 - Benzoxazinone derivatives as selective cytotoxic agents (2026-09-15),

9. 12730096 - Method for analyzing trace levels of semi-volatile nitrosamines in solid samples (2026-09-08),

10. 12723058 - NOVEL PROCESSES FOR PREPARING CONJUGATES OF THE IL-2 PROTEIN (2026-09-01),

11. 12723035 - Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as Nav1.8 inhibitors (2026-09-01),

12. 12710229 - APPARATUS AND METHOD OF MICROWAVE VACUUM DRYING STERILE PRODUCTS (2026-08-18),

13. 12709595 - NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN (2026-08-18),

14. 12703717 - Forms of antiviral nucleosides (2026-08-11),

15. 12698503 - ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY CELL-BASED POTENCY ASSAY (2026-08-04),

Company Overview

Merck Sharp & Dohme LLC, headquartered in Rahway, NJ, is a leading global pharmaceutical company dedicated to the research and development of innovative therapies. The organization specializes in a diverse range of core technologies, including BTK inhibitors, cytotoxic agents, and KRAS inhibitors, among others. With a strong focus on advancing healthcare, Merck Sharp & Dohme is committed to addressing unmet medical needs through its pioneering work in pharmaceuticals, particularly in areas such as oncology, infectious diseases, and immunology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

67 Patents

#6 in Rahway, NJ

#233 in New Jersey

#5,453 in US

#11,023 in the World

Rahway, NJ, United States of America

Merck Sharp & Dohme LLC

Forward Citations = 0

506 inventors:

Jian Liu (6 out of 40 patents)

Xavier Fradera (5 out of 24 patents)

Shuhei Kawamura (5 out of 8 patents)

4. Kira A Armacost (5 out of 5 patents)

5. Dong Xiao (4 out of 45 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Sharp & Dohme LLC. Retrieved from https://idiyas.com/company/merck-sharp-and-dohme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…